GlassScriptPhysician profile
Tiffany Maxton
NPI 1326559691
$2,522.03
in general payments reported to CMS, 2019-2025
19 companies · $194 in 2025
The $194 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $422 · 2022: $864 · 2023: $371 · 2024: $671 · 2025: $194.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,236.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $781.12 | 2021-2025 | Apretude, Dovato |
| Janssen Products, LP | $463.04 | 2021-2022 | |
| Janssen Biotech, INC. | $320.84 | 2021-2023 | Symtuza, Prezcobix |
| Exact Sciences Corporation | $276.88 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boston Scientific Corporation | $114.72 | 2022 | |
| Hologic Sales and Service, LLC | $113.38 | 2023-2024 | Aptima, Thinprep 2000 Processor |
| Lilly USA, LLC | $105.99 | 2022-2024 | Mounjaro |
| Gilead Sciences, INC. | $103.19 | 2021-2025 | |
| Glaxosmithkline, LLC. | $41.39 | 2022-2023 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.15 | 2024 | Jardiance |
| Neurocrine Biosciences, INC. | $23.57 | 2024 | Ingrezza |
| Insulet Corporation | $22.09 | 2022 | |
| Abbott Laboratories | $20.11 | 2023 | Proclaim |
| Organon LLC | $18.67 | 2024 | |
| Alkermes, INC. | $18.33 | 2025 | Lybalvi |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $18.24 | 2021 | |
| Evofem Biosciences, INC. | $16.25 | 2024 | |
| Exeltis, USA INC. | $15.70 | 2024 | Slynd |
| Cranial Technologies, INC | $14.37 | 2023 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tiffany Maxton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.